[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anxiety-disorder-generalized\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anxiety-disorder-generalized":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,83,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100643199","serotonin-variants--gut-microbiota-in-mental-health-100643199",false,"NCT07634458","Serotonin Variants & Gut Microbiota in Mental Health","Association Between Serotonin Pathway Genetic Variants and Tryptophan-Metabolizing Gut Microbiota in Adults With Mental Health Conditions: An Observational Pilot Study","Inclusion Criteria:\n\n1. Age: Adults aged 18 to 44 years.\n2. Residency: Current legal residents of the United States.\n3. Clinical Phenotype: Self-report of Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), or Panic Disorder.\n4. Medication Stability: If currently prescribed psychotropic medications (e.g., SSRIs, SNRIs, benzodiazepines), the dosage must remain stable with no changes in molecule or quantity for at least 3 months prior to enrollment.\n5. Language and Technology: Proficiency in English and access to a smartphone or computer for digital data entry.\n6. Financial Commitment: Explicit agreement to the \"Citizen Science\" model, including payment for discounted testing kits. Kit shipping (both directions) is prepaid by the study.\n\nExclusion Criteria:\n\n1. Use of systemic antibiotics, antifungals, or antivirals within the 8 weeks prior to specimen collection.\n2. Regular use of commercial probiotics or concentrated prebiotic supplements within 4 weeks of collection.\n3. Frequent use of osmotic or stimulant laxatives, or motility agents, within 4 weeks of collection.\n4. Chronic use (\\>3 times\u002Fweek) of NSAIDs, systemic corticosteroids, or high-dose Omega-3 supplementation (\\>2g\u002Fday) within 4 weeks of enrollment.\n5. Use of weight-loss medications or GLP-1 receptor agonists (e.g., semaglutide, liraglutide, tirzepatide) within the 3 months prior to enrollment.\n6. Confirmed diagnosis of Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (Crohn's or Ulcerative Colitis), Celiac Disease, or history of major gastric\u002Fintestinal resection.\n7. Current pregnancy or lactation.\n8. Presence of cognitive impairments that preclude the ability to provide informed consent.\n9. Individuals undergoing active cancer treatment.","ALL","18 Years","44 Years",{"count":20,"type":21},30,"ESTIMATED","OBSERVATIONAL","This observational pilot study investigates whether a broad panel of genetic variants relevant to the serotonin pathway (including serotonergic system, methylation cycle, intestinal barrier integrity, and inflammatory response genes) are associated with distinct gut microbiome compositional and functional signatures in adults aged 18-44 years with self-reported mental health conditions (Major Depressive Disorder, Generalized Anxiety Disorder, PTSD, or Panic Disorder).\n\nThis is a decentralized, participant-funded (Citizen Science) study. Eligible participants provide at-home saliva (buccal swab) and stool samples. Genomic analysis is performed using the NeuroBiologix GenePro+ SNP Panel (Illumina Infinium Global Screening Array-24, \\~654,000 SNPs) via Gene By Gene, a CLIA\u002FCAP-accredited laboratory. Gut microbiome analysis is performed by Tiny Health using deep whole-genome shotgun metagenomics (≥20 million reads) on a NextGen Illumina Platform.\n\nThe study is non-interventional and hypothesis-generating, aiming to identify potential genotype-microbiome associations and estimate effect sizes to inform a future interventional trial. N=30 participants. Study Start: July 2026.",[25,26,27,28],"Major Depressive Disorder (MDD","Anxiety Disorder, Generalized","Stress Disorders, Post-Traumatic","Panic Disorder",[30,31,32,33,34,35],"gut microbiome","serotonin","tryptophan metabolism","metagenomics","SNP genotyping","gut-brain axis","NOT_YET_RECRUITING","2026-06-08",{"date":39,"type":40},"2026-06-10","ACTUAL",{"date":42,"type":21},"2026-07-01",{"date":44,"type":21},"2027-09",{"name":46,"class":47},"Neurobiologix","INDUSTRY",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100611363","phase-1-act-for-individuals-with-mncd-and-their-care-partners-100611363","NCT07239609","ACT for Individuals With MNCD and Their Care Partners","Acceptance and Commitment Therapy for Individuals With MNCD and Their Care Partners: An In-Person and Telehealth Individual Therapy Approach","ACT","Inclusion Criteria\n\nInclusion (person with MCI or MNCD):\n\n* 18+\n* MMSE= 21-27\n* Able to communicate in English\n\nInclusion (care partner):\n\n* 18+\n* Identifies as a care partner of a person with MNCD\n* Able to communicate in English\n* MMSE= 28-30\n* Is a family member or friend of the person with MNCD\n\nExclusion Criteria\n\nExclusion (person with MCI or MNCD):\n\n* Currently in an intervention for reducing anxiety or depression related to their dementia\n* MMSE= 28+ or less than 21\n\nExclusion (care partner):\n\n* MMSE= \\\u003C28\n* Is a formal (paid) caregiver",true,{"count":58,"type":21},100,"INTERVENTIONAL",[61],"PHASE1","This project aims to implement and evaluate a dyadic intervention (i.e., acceptance commitment therapy) for persons with AD\u002FADRD and their care partners. We hypothesize the intervention will be feasible, acceptable, and show preliminary efficacy of the dyadic interveniotns.",[64,65,66],"Depression in Adults","Anxiety Disorder Generalized","Grief",[68,69,70],"Mild Cognitive Impariment","Mild Neurocognitive Disorder","Dyadic intervention","RECRUITING","2026-05-13",{"date":74,"type":40},"2026-05-15",{"date":76,"type":40},"2026-04-01",{"date":78,"type":21},"2027-12-31",{"name":80,"class":81},"Texas Tech University","OTHER",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":82},"100622888","evaluate-the-effects-of-long-term-use-of-psychotropic-medications-on-eye-movement-patterns-with-the-gaize-device-100622888","NCT07389473","Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device","An Observational Study to Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device","Rx Meds Gaize","Inclusion Criteria:\n\n* Adults aged between 18 and 65, having given written informed consent to participate in the research trial.\n* Currently using a psychiatric medication as prescribed by a healthcare professional for longer than 3 months.\n* Normal or corrected to normal vision using either glasses or contact lenses, or surgery.\n\nExclusion Criteria:\n\n* Enrolled in, or participated in another clinical trial within 30 days before the study\n* Having a prosthetic eye, missing eye, or wearer of an eye patch LASIK or other eye surgery within the prior 21 days.\n* Had your eyes dilated by a medical doctor in the previous 24 hours.\n* Photosensitive epilepsy\n* Diagnosed with clinical blindness\n* Medical Conditions: Participants with medical conditions or medications that could significantly affect cognitive and motor functions are excluded. Participants with conditions such as Glaucoma, macular degeneration, cataracts, lazy eye (amblyopia), or optic neuritis, or genetic anisocoria (unequal pupil size) will be excluded.\n* Current or past head inject\u002F traumatic brain injury (TBI)\n* Pregnancy: Pregnant individuals will be excluded from the study due to the potential risks associated with psychiatric medications.\n* History of Severe Motion Sickness: Participants with a history of severe motion sickness in VR environments may be excluded, as they may not tolerate the VR headset well.\n* Potential participants who are unable to provide consent for the study.","65 Years",{"count":93,"type":21},50,"The study aims to verify if the Gaize ocular device can effectively identify eye movements indicative of prescribed psychotropic medication usage by employing Drug Recognition Expert (DRE) testing protocols within a controlled virtual environment.",[96,97,98,65,99],"ADHD","Depression Disorders","Mood Disorders","Bipolar Disorder (BPD)","2026-02-04",{"date":102,"type":40},"2026-02-05",{"date":104,"type":40},"2024-04-17",{"date":106,"type":21},"2028-08",{"name":108,"class":47},"Gaize",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":119,"conditions":120,"keywords":129,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":82},"100481446","cbt-and-the-neural-circuits-of-anxiety-100481446","NCT05549102","CBT and the Neural Circuits of Anxiety","The Impact of CBT on Shock-Potentiated Neural Circuity","Inclusion Criteria:\n\n* Enrolled in IAPT Step 3 (high intensity service)\n* Score of or above 8 on the GAD-7 (indicating moderate anxiety on a standard scale of anxiety; Spitzer et al., 2006)\n* Willing and able to provide written consent\n\nExclusion Criteria:\n\n* Score above 22 on the GAD-7\n* Past\u002Fpresent psychotic disorder, bipolar disorder\u002Fmania or alcohol\u002Fsubstance use disorder (outside a comorbid psychiatric episode)\n* History of medical illness that may impair cognitive function (e.g. serious head injury, endocrine disorder)\n* Current psychotropic pharmacological intervention (e.g. SSRIs) or use within 3 months\n* MRI contraindications such as pacemaker, aneurysm clip, cochlear implant, neurostimulator, IUD, shrapnel, metal fragments in eye, weight of above 250lbs or claustrophobia\n* Females who are pregnant, planning pregnancy, or breastfeeding","64 Years",{"count":118,"type":21},174,"This study will aim to test whether specific neural circuitry changes, proposed on the basis of a neurocognitive model of anxiety, are a mechanism of action for Cognitive Behavioural Therapy (CBT) interventions. This study aims to provide a theoretical model of the neurobiological mechanisms of CBT's therapeutic effect, where there currently is none, and potentially allow for more targeted\u002Fspecific approaches to anxiety disorders following the identification of key CBT mechanisms. The ultimate aim is to improve the efficacy of CBT, and more generally, psychological interventions for anxiety disorders.",[121,122,123,124,125,126,127,65,128],"Generalised Anxiety Disorder","Anxiety Disorders","CBT","Anxiety Depression","Anxiety Disorders and Symptoms","Anxiety Generalized","Anxiety","Anxiety Disorder; Mixed With Depression (Mild)",[130,131,132,133,123,134,135,136],"GAD","generalised anxiety disorder","anxiety disorders","cognitive behavioural therapy","psychological therapy","neural circuitry","emotional processing","2025-06-25",{"date":139,"type":40},"2025-06-29",{"date":141,"type":40},"2020-02-02",{"date":143,"type":21},"2025-12-01",{"name":145,"class":81},"UCLH\u002FUCL Joint Research Office"]